PD-1/PD-L1-IN 3 ermine InChi: InChI=1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6

InChi: InChI=1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6

GSK-2981278 markedly and potently inhibits IL-17A and IL-22 protein secretion in a concentration dependent manner (IC50 = 3

50 μM) dose- and time-dependently stimulates 3T3-L1 adipogenesis after treatment for 1-10 days via activation of CB1R

and European rights to SS734 for ophthalmic use to InSite Vision Incorporated (OTCBB: INSV) in 2000

PD-1/PD-L1-IN 3 ermine InChi: InChI=1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6PD 1 PD L1 IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD 1 PD L1 and CD80 PD L1 interactions extracted from patent WO2014151634A1, compound No. 1. PD 1 PD L1 IN 3 interferes with PD L1 binding to PD 1 and CD80 by binding to PD L1, with IC50s of 5. 60 nM and 7. 04 nM, respectively. PD 1 PD L1 IN 3 can be used for the research of various diseases, including cancer and infectious diseases. Product information CAS Number: